86 related articles for article (PubMed ID: 25436812)
21. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
Heuckmann JM; Rauh D; Thomas RK
J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
[No Abstract] [Full Text] [Related]
22. First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients.
Sequist LV
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S143-5. PubMed ID: 18520299
[TBL] [Abstract][Full Text] [Related]
23. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
Ogino A; Kitao H; Hirano S; Uchida A; Ishiai M; Kozuki T; Takigawa N; Takata M; Kiura K; Tanimoto M
Cancer Res; 2007 Aug; 67(16):7807-14. PubMed ID: 17699786
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
[TBL] [Abstract][Full Text] [Related]
25. Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Heigener DF; Reck M
Adv Ther; 2011 Feb; 28(2):126-33. PubMed ID: 21181318
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Márquez-Medina D; Gasol-Cudós A; Taberner-Bonastre MT; Samamé Pérez-Vargas JC; Salud-Salvia A; Llombart-Cussac A
Arch Bronconeumol; 2013 Feb; 49(2):79-81. PubMed ID: 22627040
[TBL] [Abstract][Full Text] [Related]
27. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
Amler LC; Goddard AD; Hillan KJ
Cold Spring Harb Symp Quant Biol; 2005; 70():483-8. PubMed ID: 16869787
[TBL] [Abstract][Full Text] [Related]
28. Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.
Gauthier H; Douchet G; Lehmann-Che J; Meignin V; Raynaud C; Sabatier P; de Cremoux H; Poirot B; Culine S; Pouessel D; de Cremoux P
J Thorac Oncol; 2014 Oct; 9(10):e78-9. PubMed ID: 25521408
[No Abstract] [Full Text] [Related]
29. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
[TBL] [Abstract][Full Text] [Related]
30. [Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].
Zhang J; Gao J; Liang ZY; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):712-4. PubMed ID: 22321558
[No Abstract] [Full Text] [Related]
31. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
32. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
33. [I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].
Urata Y; Satouchi M
Gan To Kagaku Ryoho; 2015 Aug; 42(8):931-4. PubMed ID: 26353389
[No Abstract] [Full Text] [Related]
34. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
Yamada K; Aono H; Hosomi Y; Okamoto H; Kato T; Komase Y; Nishikawa M; Azuma K; Takeoka H; Okuma Y; Nakahara Y; Sato A; Oba MS; Morita S; Kunitoh H; Watanabe K
Eur J Cancer; 2015 Sep; 51(14):1904-10. PubMed ID: 26174465
[TBL] [Abstract][Full Text] [Related]
35. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
Das AK; Sato M; Story MD; Peyton M; Graves R; Redpath S; Girard L; Gazdar AF; Shay JW; Minna JD; Nirodi CS
Cancer Res; 2006 Oct; 66(19):9601-8. PubMed ID: 17018617
[TBL] [Abstract][Full Text] [Related]
36. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
[TBL] [Abstract][Full Text] [Related]
37. Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer.
Chen CM; Chang JW; Cheung YC; Lin G; Hsieh JJ; Hsu T; Huang SF
Acta Radiol; 2008 Nov; 49(9):991-4. PubMed ID: 18651255
[TBL] [Abstract][Full Text] [Related]
38. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
Inoue A; Kobayashi K; Usui K; Maemondo M; Okinaga S; Mikami I; Ando M; Yamazaki K; Saijo Y; Gemma A; Miyazawa H; Tanaka T; Ikebuchi K; Nukiwa T; Morita S; Hagiwara K;
J Clin Oncol; 2009 Mar; 27(9):1394-400. PubMed ID: 19224850
[TBL] [Abstract][Full Text] [Related]
39. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Inoue Y; Inui N; Asada K; Karayama M; Matsuda H; Yokomura K; Koshimizu N; Imokawa S; Yamada T; Shirai T; Kasamatsu N; Suda T
Cancer Chemother Pharmacol; 2015 Jul; 76(1):155-61. PubMed ID: 26003540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
